Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-α carriers: Pharmacokinetics and anti-tumor effects

47Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

The objective of this study was to investigate the pharmacokinetics and in vivo anti-tumor effect of recombinant human tumor necrosis factor-α (rHuTNF-α) encapsulated in poly (methoxypolyethyleneglycol cyanoacrylate-co-n-hexadecyl cyanoacrylate) (PEG-PHDCA) nanoparticles. Our experimental results showed that PEG-PHDCA nanoparticles could extend the half-life of rHuTNF-α to 7.42 h and obviously change the protein biodistribution in tissues, and in particular, increase accumulation of rHuTNF-α in tumor. Compared with PHDCA nanoparticles and free rHuTNF-α, PEG-PHDCA nanoparticles loaded with rHuTNF-α showed higher anti-tumor potency at the same dose, which might be related to its higher accumulation in tumor tissues and longer plasma circulation time. Therefore, PEG-PHDCA nanoparticles could be an effective carrier for rHuTNF-α.

Cite

CITATION STYLE

APA

Li, Y. P., Pei, Y. Y., Zhou, Z. H., Zhang, X. Y., Gu, Z. H., Ding, J., … Zhu, J. H. (2001). Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-α carriers: Pharmacokinetics and anti-tumor effects. Biological and Pharmaceutical Bulletin, 24(6), 662–665. https://doi.org/10.1248/bpb.24.662

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free